Recent preclinical and clinical studies have shown that in response to successful androgen/AR blockade, AR-positive prostate cancers may switch to androgen/AR-independent pathways for survival and growth, thereby conferring therapy resistance and enabling disease progression13,14. Here, AR is linked to prostate cancer.